- Home
- PBPB vs DMAC Comparison
PBPB vs DMAC Comparison
Compare PBPB & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBPB
- DMAC
- Stock Information
- Founded
- PBPB 1977
- DMAC 2000
- Country
- PBPB United States
- DMAC United States
- Employees
- PBPB N/A
- DMAC N/A
- Industry
- PBPB Restaurants
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- PBPB Consumer Discretionary
- DMAC Health Care
- Exchange
- PBPB Nasdaq
- DMAC Nasdaq
- Market Cap
- PBPB 305.0M
- DMAC 310.1M
- IPO Year
- PBPB 2013
- DMAC N/A
- Fundamental
- Price
- PBPB $12.55
- DMAC $6.71
- Analyst Decision
- PBPB Strong Buy
- DMAC Strong Buy
- Analyst Count
- PBPB 2
- DMAC 3
- Target Price
- PBPB $17.50
- DMAC $12.33
- AVG Volume (30 Days)
- PBPB 204.7K
- DMAC 345.3K
- Earning Date
- PBPB 11-06-2025
- DMAC 08-12-2025
- Dividend Yield
- PBPB N/A
- DMAC N/A
- EPS Growth
- PBPB N/A
- DMAC N/A
- EPS
- PBPB 0.35
- DMAC N/A
- Revenue
- PBPB $469,138,000.00
- DMAC N/A
- Revenue This Year
- PBPB $5.28
- DMAC N/A
- Revenue Next Year
- PBPB $4.30
- DMAC N/A
- P/E Ratio
- PBPB $36.52
- DMAC N/A
- Revenue Growth
- PBPB N/A
- DMAC N/A
- 52 Week Low
- PBPB $7.27
- DMAC $3.19
- 52 Week High
- PBPB $13.67
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- PBPB 50.44
- DMAC 68.50
- Support Level
- PBPB $12.19
- DMAC $5.14
- Resistance Level
- PBPB $13.18
- DMAC $6.16
- Average True Range (ATR)
- PBPB 0.41
- DMAC 0.38
- MACD
- PBPB -0.03
- DMAC -0.02
- Stochastic Oscillator
- PBPB 49.61
- DMAC 61.28
About PBPB Potbelly Corporation
Potbelly Corp owns and franchises hundreds of limited-service restaurants specializing in sandwiches and salads, shakes. The menu includes toasty sandwiches, signature salads, soups, chili, sides, desserts, and, in breakfast locations it serves breakfast sandwiches and steel-cut oatmeal. majority of its locations are company-owned and located in the United States, with Illinois and Texas housing far more locations than any other state. The company has franchise partners in a number of countries. Excluding the United States, its franchises are in the Middle East.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.